From discovery to dose: Advancing small molecule and highly potent platform drug substance In 2025, CordenPharma reinforced our Small Molecule Drug Substance capabilities with major investments designed to meet growing customer demand. In Liestal (CH), we are wrapping up a fiveyear facility renovation to expand purification and small-scale development capacity. Our Chenôve (FR) site now features new 6,000 L reactors with enhanced isolation and drying capability, while our Bergamo (IT) facility added a 12,000 L multi product, state-of-the-art manufacturing line, plus upgraded warehousing and increased hydrogenation infrastructure. These enhancements provide customers with substantial, ready-to-use capacity for both standard and highly potent small molecule APIs. Our small molecule drug substance services guide innovators through every stage of API development, from route scouting and process optimization to purification, micronization, solidstate design, and continuous flow chemistry. By addressing complex chemical, stability, and bioavailability challenges early, we reduce risk, accelerate timelines, and ensure scalable, highquality supply. Solid-state optimization remains central to our approach. We support customers with polymorph screening, salt and co-crystal selection, solubility testing, and tailored crystallization development designed to deliver robust APIs that perform reliably in downstream formulations. Advanced analytical tools, including DSC, TGA-FTIR, DVS, particle size distribution, and X-ray diffraction, provide the data needed to move confidently through development and regulatory review. For highly potent APIs, our US Colorado facility offers secure, scalable containment for APIs with occupational exposure limits as low as 0.05 µg/m³. By combining process optimization and purification under cGMP, we deliver high potency APIs with minimal risk and maximum reliability from early clinical supply to commercial scale. At Chenôve (FR), our Flow Chemistry Centre of Excellence enables customers to tackle complex reactions that are challenging in batch mode, including electrochemistry and photochemistry, opening access to a wider range of molecules faster and more efficiently. 16DAILY NEWS CPHI 2025 FRANKFURT DAY 1 | 28th October 2025
RkJQdWJsaXNoZXIy MjY2OTA4MA==